Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mccallum, R. W
Right arrow Articles by Fisher, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes

Roland W Mccallum

Miles Fisher

Wards 4 & 5, Glasgow Royal Infirmary, 84 Castle Street, Glasgow, G4 0SF, UK? miles.fisher{at}northglasgow.scot.nhs.uk

he last ten years have seen a rapid expansion in the evidence-base for the reduction of cardiovascular risk in people with diabetes.in Following the landmark Scandinavian Simvastatin Survival Study (4S), several other studies have shown the benefits of statins in people with diabetes, but much less data are available for the benefit of fibrates, and the main evidence to date comes from subgroup analysis of the Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial (VA-HIT). The Hypertension in Diabetes Study (HDS), nested within the United Kingdom Prospective Diabetes Study (UKPDS), proved that tight control of hypertension reduced microvascular and macrovascular events in people with diabetes, and the Heart Outcomes Prevention Evaluation (HOPE) and MICRO-HOPE studies suggested a benefit in reducing cardiovascular events with angiotensin-converting enzyme (ACE) inhibition, additional to blood pressure lowering effects. With regards to glycaemic therapy, the UKPDS has shown the benefit of metformin in reducing myocardial infarctions. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) studies will be presented later this year and will give information on the role of fenofibrate and pioglitazone respectively in reducing cardiovascular events in people with diabetes.

Key Words: diabetes • cardiovascular disease • statins • fibrates • hypertension • ACE inhibitors • metformin

References

  • Fisher M., Shaw K. Diabetes: a state of premature cardiovascular death. Pract Diab Int 2001;18:183-4.[CrossRef]
  • Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pyorala K., Pedersen TR, Kjekshus J., Faergeman O., Olsson AG, Thorgeirsson G. & the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
  • Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-09.[Abstract/Free Full Text]
  • Goldberg RB, Mellies MJ, Sacks FM et al. for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998;98:2513-19.[Abstract/Free Full Text]
  • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.[Abstract/Free Full Text]
  • Keech A., Colquhoun D., Best J. et al. for the LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Results from the LIPID trial. Diabet Care 2003;26:2713-21.[Abstract/Free Full Text]
  • Shepherd J., Cobbe S., Ford I. et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333:1301-07.[Abstract/Free Full Text]
  • Downs JR, Clearfield M., Weis S. et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.[Abstract/Free Full Text]
  • Collins R., Armitage J., Parish S., Sleigh P., Peto R., for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Colihoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Marshall G., McDougall C., Brady A., Fisher M. Should all diabetic patients receive a statin? Results from recent trials. Br J Cardiol 2004;11:455-60.
  • Cannon CP, Braunwald E., McCabe CH et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.[Abstract/Free Full Text]
  • LaRosa JC, Grundy SM, Waters DD et al. The Treating to New Targets (TNT) Investigators. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med 2005;352:1424-35.[CrossRef]
  • Rubins H., Robins SJ, Collins D. et al. for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.[Abstract/Free Full Text]
  • Rubins H., Robins SJ, Collins D. et al. for the VA-HIT Study Group. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002;162:2597-604.[Abstract/Free Full Text]
  • The FIELD Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (Field) study. Cardiovasc Diabetol 2004;3:9.[CrossRef][Medline] [Order article via Infotrieve]
  • UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.[Abstract/Free Full Text]
  • UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.[Abstract/Free Full Text]
  • Hansson L., Zanchetti A., Carruthers SG et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lithell H., Berglund L. Validation of an oscillometric blood pressure measuring device: a substudy of the HOT study. Hypertension Optimal Treatment. Blood Press 1998;7:149-52.
  • Adler AI, Stratton IM, Neil HAW et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-19.[Abstract/Free Full Text]
  • Neal B., McMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 1000;356:1955-64.
  • Anonymous. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.[Abstract/Free Full Text]
  • Sever PS, Dahlof B., Poulter NR et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac outcomes Trial. ASCOT investigators. J Hypertens 2001;19:1139-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kirby M. Has ASCOT signalled the end for beta blockers as first-line antihypertensive agents? Br J Diabetes Vasc Dis 2005;5:100-02.[Abstract/Free Full Text]
  • Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gerstein H. Cardiovascular and Metabolic Benefits of ACE Inhibition. Diab Care 2000;23:882-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fox KM EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Braunwald E., Domanski MJ, Fowler SE et al. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.[Abstract/Free Full Text]
  • Fisher BM Hypertension in diabetes: diuretic, ACE inhibitor or AIIRA? [Leader] Pract Diab Int 2003;20:232-3.
  • UKPDS 1 Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. UKPDS Study Group. Diabetol 1983;24:404-11.
  • UKPDS 34 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. UKPDS Study Group. Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Charbonnel B., Dormandy JA, Erdmann E. et al. on behalf of the PROactive Study Group. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive). Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabet Care 2004;27:1647-753.[Abstract/Free Full Text]
  • ADVANCE Management Committee. ADVANCE: action in diabetes and vascular disease. Preterax and diamicron MR controlled evaluation. Study design and rationale. Diabetol 2001;44:1118-20.[CrossRef]
  • Barwell N., Fisher BM What are the beneficial and adverse effects of aspirin in diabetic patients? [Leader] Pract Diab Int 2004;21:131-2.[CrossRef]
  • Nathan DM Some answers, more controversy from UKPDS: United Kingdom Prospective Diabetes Study. Lancet 1998;352:832-3.[Web of Science][Medline] [Order article via Infotrieve]
  • Blumfield JD, Sealey JE, Mann SJ et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kirby M. ASCOT-lipid lowering arm. Br J Diabetes Vasc Dis 2003;3:200-01.[Abstract/Free Full Text]
  • Gaede P., Pernille V., Larsen N. et al. Multifactorial Intervention and Cardiovascular Disease in patients with Type 2 Diabetes (Steno-2).N Engl J Med 2008;348:383-93[CrossRef]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 4, 218-225 (2005)
DOI: 10.1177/14746514050050040701
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Diabetes and Vascular Disease ResearchHome page
R. A Ajjan and P. J Grant
Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents
Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 147 - 158.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
R. W Mccallum and M. Fisher
Review: Comparing cardiovascular outcomes in diabetes studies
The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 111 - 118.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
J. P Vora
Editorial
The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2_suppl): S1 - S1.
[PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
M. Fisher and I. W Campbell
Residual cardiovascular risk and practical management of type 2 diabetes
The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2_suppl): S17 - S23.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
I. W Campbell
PROactive Study: PROspective pioglitAzone Clinical Trial In macroVascular Events
The British Journal of Diabetes & Vascular Disease, September 1, 2005; 5(5): 272 - 274.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mccallum, R. W
Right arrow Articles by Fisher, M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?